A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial spondyloarthritis who achieved remission

Published: 21-12-2022
Last updated: 30-11-2024

This study has been transitioned to CTIS with ID 2023-509320-17-00 check the CTIS register for the current data. * To evaluate whether continuous secukinumab treatment is superior to placebo in preventing flares during Treatment Period 2 in...

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Autoimmune disorders
Study type	Interventional

Summary

ID

NL-OMON55967

Source
ToetsingOnline

Brief title
CAIN457i2401

Condition

- Autoimmune disorders
- Joint disorders

Synonym

non-radiographic spondyloartritis

Research involving
Human

Sponsors and support

Primary sponsor: Novartis
Source(s) of monetary or material Support: Novartis Pharma B.V. (sponsor/verrichter van dit onderzoek)

Intervention

Keyword: non-radiographic axial Spondylarthritis, nr-AxSpA, Remission, Secukinumab

Outcome measures

Primary outcome

* The proportion of participants remaining flare-free at Week 120

Secondary outcome

* Time to flare during Treatment Period 2

* Safety and tolerability demonstrated by assessing:

* Adverse events (AEs) and serious adverse events (SAEs) (incidence,

severity, and relationship with study drug)

* Clinically significant changes in laboratory parameters and vital

signs

Study description

Background summary

This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with nr-axSpA (non-radiographic axial spondyloarthritis) who have achieved remission.

Study objective

This study has been transitioned to CTIS with ID 2023-509320-17-00 check the CTIS register for the current data.

* To evaluate whether continuous secukinumab treatment is superior to placebo in preventing flares during Treatment Period 2 in participants who achieved a state of remission in Treatment Period 1
* To evaluate efficacy of secukinumab on preventing the onset of flares in participants in a state of remission during Treatment Period 2 in participants who achieved a state of remission in Treatment Period 1
* To assess overall safety and tolerability of secukinumab over time up to follow-up visit

Study design

This phase IV, multicenter study uses a double-blind, placebo-controlled, randomized withdrawal design (Treatment Period 2) preceded by an open label lead-in period (Treatment Period 1).

Intervention

Secukinumab (AIN457) 150 mg s.c. (subcutaneously) and placebo s.c.

All eligible participants who enter Treatment Period 1 will receive open-label secukinumab 150 mg administered s.c. at Baseline, Weeks 1, 2, 3, and 4 and then every 4 weeks up to and including Week 52.

During Treatment Period 2, participants will be randomized 1:1 at Week 56 to one of the following groups and will receive the first dose of blinded treatment at Week 56.
• Group 1: 150 mg secukinumab s.c. at Week 56 and every 4 weeks thereafter through to Week 116 or until a flare
• Group 2: placebo s.c. at Week 56 and every 4 weeks thereafter through to Week 116 or until a flare
Participants who meet flare criteria in Treatment Period 2, regardless if they were randomized to secukinumab or placebo, will receive an escape re-treatment with an open-label 150 mg secukinumab s.c. every 4 weeks starting from the next scheduled visit after the one at which a participant met flare criteria.

Study burden and risks

Visits: 25x (max), 1-2 hours
MRI: 1x (unless already performed in the 3 months prior to the screening)
X-ray sacroiliac joint: 1x (unless already performed in the 3 months prior to the screening)
X-Thorax: 1x (unless already performed in the 3 months prior to the screening)
Physical exam: 7x in period 1, 18x in period 2

Height: 1x
Weight: 1x in period 1, 2x in period 2
Vital Signs: 7x in period 1, 18x in period 2
TB-test: 1x
Urinalysis: 7x in period 1, 7x in period 2
Pregnancytest (serum): 1x (in case patient can become pregnant)
Pregnancytest (urine): 6x in period 1, 8x in period 2 (in case patient can become pregnant)
Hepatitis B/C and HIV: 1x in case locally required
ePROs (6x): 3-6x in period 1, 6-17x in period 2
Feedback questionnaire: 2x in period 1, 1x in period 2

Contacts

Public
Novartis

Haaksbergweg 16
Amsterdam 1101 BX
NL
Scientific
Novartis

Haaksbergweg 16
Amsterdam 1101 BX
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

• Male or non-pregnant, non-lactating female participants at least 18 years of age
• Clinical diagnosis of axSpA AND according to ASAS axSpA criteria:
a. Inflammatory back pain for at least 6 months
b. Onset before 45 years of age
c. Sacroiliitis on MRI (magnetic resonance imaging) (as assessed by central reader) with >= 1 SpA feature OR HLA-B-27 positive with >=2 SpA features
• Objective signs of inflammation at screening, evident by either
MRI with Sacroiliac Joint inflammation (as assessed by central reader)
AND / OR
hsCRP > ULN (as defined by the central lab)
• Active axSpA as assessed by total BASDAI >= 4 cm (0-10 cm) at baseline.
• Spinal pain as measured by BASDAI question #2 >= 4 cm (0-10 cm) at baseline.
• Total back pain as measured by VAS (visual analog scale) >= 40 mm (0-100 mm) at baseline.
• Participants should have been on at least 2 different NSAIDs (non-steroidal anti-inflammatory drugs) at the highest recommended dose for at least 4 weeks in total prior to baseline with an inadequate response or failure to respond, or less if therapy had to be withdrawn due to intolerance, toxicity or contraindications.

Exclusion criteria

Key Exclusion criteria
• Participants with radiographic evidence for sacroiliitis, grade >= 2 bilaterally or grade >= 3 unilaterally (radiological criterion according to the modified New York diagnostic criteria for AS) as assessed by central reader.
• Participants taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine).
• Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor or previous treatment with immunomodulatory biologic agents including those targeting TNFα (tumor necrosis factor α) (unless participants discontinued the treatment with TNFα inhibitor due to a reason other than efficacy [primary or secondary lack of efficacy, inadequate response] and only after appropriate wash-out period prior to baseline was observed).
• History of hypersensitivity to the study drug or its excipients or to drugs of similar chemical classes.
• Active ongoing inflammatory diseases other than nr-axSpA that might confound the evaluation of the benefit of secukinumab therapy, including uveitis.
• Active inflammatory bowel disease.
• History of ongoing, chronic or recurrent infectious disease or evidence of

tuberculosis infection.

Study design

Design

Study phase:	4
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	16-11-2023
Enrollment:	9
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Cosentyx
Generic name:	secukinumab
Registration:	Yes - NL intended use

Ethics review

Approved WMO

Date:	21-12-2022
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Approved WMO Date:	06-02-2023
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	25-02-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	03-03-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	17-10-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	24-10-2023
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EU-CTR	CTIS2023-509320-17-00
EudraCT	EUCTR2022-001153-23-NL
CCMO	NL83135.056.22